Search results for "Agent"

showing 10 items of 8904 documents

Origin of modern syphilis and emergence of a pandemic Treponema pallidum cluster

2016

The abrupt onslaught of the syphilis pandemic that started in the late fifteenth century established this devastating infectious disease as one of the most feared in human history1 . Surprisingly, despite the availability of effective antibiotic treatment since the mid-twentieth century, this bacterial infection, which is caused by Treponema pallidum subsp. pallidum (TPA), has been re-emerging globally in the last few decades with an estimated 10.6 million cases in 2008 (ref. 2). Although resistance to penicillin has not yet been identified, an increasing number of strains fail to respond to the secondline antibiotic azithromycin3. Little is known about the genetic patterns in current infec…

0301 basic medicineMicrobiologia340 LawCiencias de la SaludAzithromycinGlobal HealthBacterisApplied Microbiology and Biotechnology2726 Microbiology (medical)1307 Cell BiologyGenotypePandemicPhylogenyMolecular EpidemiologyTreponemaPhylogenetic treebiology2404 Microbiology10177 Dermatology ClinicTREPONEMA PALLIDUM10218 Institute of Legal MedicineAnti-Bacterial Agents3. Good health590 Animals (Zoology)//purl.org/becyt/ford/3 [https]ORIGIN OF SYPHILISMalalties de transmissió sexualDNA BacterialMicrobiology (medical)CIENCIAS MÉDICAS Y DE LA SALUDGenotypeImmunology610 Medicine & healthMicrobiologyEvolution Molecular//purl.org/becyt/ford/3.3 [https]10127 Institute of Evolutionary Biology and Environmental Studies03 medical and health sciences1311 GeneticsPhylogeneticsDrug Resistance BacterialGeneticsmedicine2402 Applied Microbiology and BiotechnologyHumansSyphilisTreponema pallidumPandemics2403 ImmunologyMolecular epidemiologyGenetic VariationSequence Analysis DNACell Biologymedicine.diseasebiology.organism_classificationVirologyEnfermedades Infecciosas030104 developmental biologyInfectious disease (medical specialty)570 Life sciences; biologySyphilisGenome Bacterial
researchProduct

What happens in hospitals does not stay in hospitals: antibiotic-resistant bacteria in hospital wastewater systems.

2016

Hospitals are hotspots for antimicrobial-resistant bacteria (ARB) and play a major role in both their emergence and spread. Large numbers of these ARB will be ejected from hospitals via wastewater systems. In this review, we present quantitative and qualitative data of extended-spectrum β-lactamase (ESBL)-producing Escherichia coli, vancomycin-resistant enterococci and Pseudomonas aeruginosa in hospital wastewaters compared to community wastewaters. We also discuss the fate of these ARB in wastewater treatment plants and in the downstream environment. Published studies have shown that hospital effluents contain ARB, the burden of these bacteria being dependent on their local prevalence. The…

0301 basic medicineMicrobiology (medical)030106 microbiologyWastewater010501 environmental sciencesurologic and male genital diseasesmedicine.disease_cause01 natural sciencesbeta-LactamasesVancomycin-Resistant EnterococciWater Purification03 medical and health sciencesAntibiotic resistance[ SDV.MP ] Life Sciences [q-bio]/Microbiology and ParasitologyDrug Resistance BacterialEscherichia colimedicineHumansVancomycin-resistant EnterococcusSelection GeneticEffluentComputingMilieux_MISCELLANEOUS0105 earth and related environmental sciencesPseudomonas aeruginosabusiness.industryGeneral MedicineAntimicrobialHospitals6. Clean waterAnti-Bacterial Agents3. Good healthBiotechnologyMultiple drug resistanceInfectious Diseases[SDV.MP]Life Sciences [q-bio]/Microbiology and ParasitologyWastewater13. Climate actionPseudomonas aeruginosaSewage treatmentbusiness
researchProduct

Genome-wide Association Study Identifies Genetic Variants Associated With Early and Sustained Response to (Pegylated) Interferon in Chronic Hepatitis…

2019

Wong, Grace LH/0000-0002-2863-9389; Wong, Vincent WS/0000-0003-2215-9410; Mangia, A/0000-0002-2600-3555; Brahmania, Mayur/0000-0002-4671-1479; Chan, Henry Lik-Yuen/0000-0002-7790-1611; Brouwer, Willem Pieter/0000-0001-8713-1481; Feld, Jordan/0000-0003-2640-2211; Tanwandee, Tawesak/0000-0001-7634-0843; Jaroszewicz, Jerzy/0000-0003-0139-4753; Chuaypen, Natthaya/0000-0002-5415-510X

0301 basic medicineMicrobiology (medical)AdultMaleHBsAgHepatitis B virusSettore MED/09 - Medicina InternaGenotyping TechniquesGenome-wide association studymedicine.disease_causePeripheral blood mononuclear cellAntiviral Agents03 medical and health sciences0302 clinical medicineHepatitis B ChronicSDG 3 - Good Health and Well-beingPegylated interferonInterferonmedicineHumansGWASchronic hepatitis BgeneticsProspective StudiespeginterferonArticles and CommentariesHepatitis B virusresponsebusiness.industryInterleukinInterferon-alphaMiddle Aged3. Good health030104 developmental biologyInfectious DiseasesHBeAgImmunologyMultivariate Analysis030211 gastroenterology & hepatologyFemaleInterferonsbusinessmedicine.drugGenome-Wide Association StudyClinical Infectious Diseases
researchProduct

In vitro activity of anidulafungin in combination with amphotericin B or voriconazole against biofilms of five Candida species

2016

Objectives: To evaluate the in vitro activity of anidulafungin combined with amphotericin B or voriconazole against Candida spp. biofilms. Methods: Four Candida albicans, four Candida tropicalis, four Candida glabrata, two Candida parapsilosis and two Candida orthopsilosis blood isolates were tested by the microdilution chequerboard method combined with the XTT metabolic assay. Biofilm MIC was defined as the lowest concentration producing 50% metabolic inhibition with respect to control (BMIC50). Concentrations in the combinations ranged from 1/8xBMIC(50) to 4xBMIC(50) found for each antifungal tested alone. Results: Anidulafungin plus amphotericin B acted synergistically against C. albican…

0301 basic medicineMicrobiology (medical)Antifungal Agents030106 microbiologyMicrobial Sensitivity TestsCandida parapsilosisAnidulafunginMicrobiologyCandida tropicalis03 medical and health sciencesEchinocandinsAmphotericin BAmphotericin BmedicineHumansPharmacology (medical)Candida albicansCandidaPharmacologyVoriconazolebiologyCandida glabrataChemistryCandidemiaDrug Synergismbiology.organism_classificationbacterial infections and mycosesCorpus albicansInfectious DiseasesBiofilmsAnidulafunginVoriconazolemedicine.drug
researchProduct

(1,3)-β-d-Glucan-based antifungal treatment in critically ill adults at high risk of candidaemia: an observational study.

2016

OBJECTIVES To determine the effects of a strategy that uses serum (1,3)-β-d-glucan (BDG) results for antifungal treatment of ICU patients at high risk of invasive candidiasis. PATIENTS AND METHODS Adult patients admitted to the ICU from January 2012 to June 2014 were included if they exhibited sepsis at the time of BDG testing and they met Candida score components ≥3. A retrospective analysis of collected data was performed. RESULTS In total, 198 patients were studied. Of 63 BDG-positive patients, 47 with candidaemia and 16 with probable Candida infection, all [31.8% (63/198)] received antifungal therapy. Of 135 BDG-negative patients, 110 [55.5% (110/198)] did not receive antifungal therapy…

0301 basic medicineMicrobiology (medical)AntifungalAdultMalemedicine.medical_specialtyAntifungal AgentsAntigens Fungalbeta-GlucansLetterAdolescentMedicine (all); Pharmacology; Infectious Diseases; Pharmacology (medical)medicine.drug_classCritical Illness030106 microbiologyAntifungal drugSettore MED/17 - MALATTIE INFETTIVESettore MED/07 - MICROBIOLOGIA E MICROBIOLOGIA CLINICAlaw.inventionSepsis03 medical and health sciencesYoung AdultlawInternal medicineSepsismedicineHumansPharmacology (medical)Candidiasis InvasiveMedical prescriptionYoung adultCandidaAgedRetrospective StudiesPharmacologyAged 80 and overbusiness.industryMedicine (all)Retrospective cohort studyMiddle Agedmedicine.diseaseIntensive care unitSurgeryInfectious DiseasesObservational studyFemaleProteoglycansbusinessThe Journal of antimicrobial chemotherapy
researchProduct

Antifungal prophylaxis: update on an old strategy.

2016

0301 basic medicineMicrobiology (medical)Antifungalmedicine.medical_specialtyAntifungal Agentsmedicine.drug_class030106 microbiologyMycoseAntifungal drugChemoprevention03 medical and health sciences0302 clinical medicineMedical microbiologyInternal medicineMedicineAntifungal AgentHumansMED/41 - ANESTESIOLOGIAbusiness.industry030208 emergency & critical care medicineGeneral MedicineInfectious DiseasesMycosesbusinessFluconazolemedicine.drugHuman
researchProduct

Positive Role of the MHC Class-I Antigen Presentation Regulator m04/gp34 of Murine Cytomegalovirus in Antiviral Protection by CD8 T Cells

2020

Murine cytomegalovirus (mCMV) codes for MHC class-I trafficking modulators m04/gp34, m06/gp48, and m152/gp40. By interacting with the MHC class-Iα chain, these proteins disconnect peptide-loaded MHC class-I (pMHC-I) complexes from the constitutive vesicular flow to the cell surface. Based on the assumption that all three inhibit antigen presentation, and thus the recognition of infected cells by CD8 T cells, they were referred to as “immunoevasins.” Improved antigen presentation mediated by m04 in the presence of m152 after infection with deletion mutant mCMV-Δm06W, compared to mCMV-Δm04m06 expressing only m152, led us to propose renaming these molecules “viral regulators of antigen present…

0301 basic medicineMicrobiology (medical)BAC mutagenesisMuromegalovirusAdoptive cell transfer030106 microbiologyImmunologyAntigen presentationMutantlcsh:QR1-502CD8 T cellsPeptide bindingCD8-Positive T-LymphocytesMajor histocompatibility complexAntiviral AgentsMicrobiologylcsh:MicrobiologyMiceViral Proteins03 medical and health sciencesCellular and Infection MicrobiologyMHC class IAnimalsCytotoxic T cellnext-generation sequencing (NGS)adoptive cell transferimmune evasionAntigen PresentationMembrane GlycoproteinsbiologyMHC class I antigenHistocompatibility Antigens Class IimmunoevasinBrief Research ReportCell biology030104 developmental biologyInfectious Diseasesbiology.proteinrecombinant virusFrontiers in Cellular and Infection Microbiology
researchProduct

Whole-genome characterization of Shewanella algae strain SYT3 isolated from seawater reveals insight into hemolysis.

2018

Aim: To describe the genomic characteristics of seawater-borne hemolytic Shewanella algae and its resistance genes. Materials & methods: Whole genome sequence of S. algae SYT3 was determined using llumina MiSeq platform. Multiple-database-based analysis was performed to identify the genetic background of its hemolytic activity and the antibiotic resistance genes. Results: S. algae SYT3 possesses a homolog of the hly operon involved in the synthesis of hemolysin. We also identified candidate genes associated with resistance to β-lactam antibiotics (bla OXA-55) and fluoroquinolone (qnrA3). Conclusion: The study provides an insight into the hemolytic activity of S. algae. Our findings als…

0301 basic medicineMicrobiology (medical)DNA BacterialShewanellaOperon030106 microbiologyTaiwanShewanella algaeMicrobial Sensitivity TestsMicrobiologyGenomeHemolysisbeta-LactamasesMicrobiology03 medical and health sciencesHemolysin ProteinsAntibiotic resistanceAlgaeBacterial ProteinsRNA Ribosomal 16SDrug Resistance BacterialmedicineHumansSeawaterGenePhylogenyWhole genome sequencingbiologyWhole Genome SequencingChromosome Mappingbiology.organism_classificationmedicine.diseaseHemolysisAnti-Bacterial AgentsBacterial Typing TechniquesGenome BacterialFuture microbiology
researchProduct

Early adjustment of empirical antibiotic therapy of bloodstream infections on the basis of direct identification of bacteria by matrix-assisted laser…

2020

Abstract Introduction To assess the potential added value of rapid MALDI-TOF MS-based identification of bacteria in positive blood cultures to the information provided by Gram staining for adequate empirical antibiotic treatment adjustments in patients with bloodstream infections (BSI). Methods We conducted a retrospective, single-center, pre-post quasi-experimental study. In the pre-MALDI-TOF MS phase of the study antibiotic adjustments were made on the basis of Gram stain results, whereas in the MALDI-TOF MS phase they were based on information provided by Gram staining and MALDI-TOF MS results. No antimicrobial stewardship program for BSI was in place within the study period. Antibiotic …

0301 basic medicineMicrobiology (medical)EnterobacterialesBacillimedicine.medical_specialtymedicine.drug_class030106 microbiologyAntibioticsBacteremialaw.invention03 medical and health sciences0302 clinical medicinelawSepsisInternal medicinemedicineHumansAntimicrobial stewardshipPharmacology (medical)Blood culture030212 general & internal medicineRetrospective StudiesBacteriaStaining and Labelingbiologymedicine.diagnostic_testbusiness.industryLasersbiology.organism_classificationmedicine.diseaseAnti-Bacterial AgentsInfectious DiseasesGram stainingSpectrometry Mass Matrix-Assisted Laser Desorption-IonizationBacteremiabusinessBacteriaJournal of Infection and Chemotherapy
researchProduct

What can evolutionary rescue tell us about the emergence of new resistant bacteria?

2017

0301 basic medicineMicrobiology (medical)GeneticsBacteriaGene Transfer HorizontalPhage therapymedicine.medical_treatment030106 microbiologyBacterial InfectionsBiologyMicrobiologyAnti-Bacterial AgentsMicrobiologyEvolution Molecular03 medical and health sciencesResistant bacteriaAntibiotic resistanceDrug Resistance BacterialMutationHorizontal gene transfermedicineHumansSelection GeneticEvolutionary rescueFuture Microbiology
researchProduct